In the BioHarmony Drug Report Database

"Preview" Icon

Prazosin

Minipress, Minipress Xl (prazosin) is a small molecule pharmaceutical. Prazosin was first approved as Minipress on 1982-01-01. It is used to treat hypertension, prostatic hyperplasia, raynaud disease, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor. In addition, it is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, alpha-2C adrenergic receptor, and ribosyldihydronicotinamide dehydrogenase [quinone].

 

Trade Name

 

Minipress, Minipress Xl
 

Common Name

 

prazosin
 

ChEMBL ID

 

CHEMBL2
 

Indication

 

hypertension, prostatic hyperplasia, raynaud disease, urinary retention
 

Drug Class

 

Antihypertensives (prazosin type)

Image (chem structure or protein)

Prazosin structure rendering